Review3 Biotech2025
Biocompatible nanostructured chitosan scaffolds for enhanced diabetic wound healing: Innovations and strategies.
Review in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanostructured chitosan scaffolds have shown significant promise in promoting diabetic wound healing due to their excellent biocompatibility, biodegradability, and regenerative capabilities. These scaffolds possess high porosity and mechanical stability, supporting optimal cell adhesion, proliferation, and extracellular matrix deposition. They accelerate wound repair, achieving 40-60% faster wound closure, a two-to-threefold increase in collagen synthesis, and up to a 200% rise in vascular endothelial growth factor (VEGF) expression. Both in vitro and in vivo studies demonstrate enhanced wound closure, increased collagen deposition, and upregulated VEGF expression, promoting angiogenesis and tissue regeneration. Chitosan scaffolds also modulate key molecular pathways, effectively reducing oxidative stress and inflammation while stimulating cellular repair mechanisms. Recent advancements in fabrication techniques, such as nanotechnology, 3D printing, and electrospinning, have improved scaffold adaptability, enabling the development of multifunctional wound dressings with controlled drug release and enhanced bioactivity. Furthermore, chitosan-based scaffolds exhibit inherent antimicrobial, antioxidant, and anti-inflammatory properties, making them particularly suitable for managing chronic diabetic wounds. The incorporation of bioactive compounds, nanoparticles, and growth factors has further enhanced their therapeutic efficacy. While preclinical studies show promising outcomes, additional research is necessary to ensure clinical translation and large-scale production. This review highlights the potential of chitosan-based scaffolds as innovative biomaterials for diabetic wound management and their promising prospects for future clinical applications. Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-025-04377-4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.